Ceryvyn Therapeutics Limited (ASX:CYV), formerly known as Opthea Limited, is a clinical-stage biopharmaceutical company developing therapies for patients with serious diseases. Following a strategic pivot, the company is now focused on advancing its lead program, CYV-101 (formerly OPT-302), in lymphangioleiomyomatosis (LAM) — a rare, chronic, and progressive pulmonary disease that predominantly affects women. The company's performance is governed by the progress of its preclinical and clinical programs, cash management, and its ability to advance CYV-101 through a defined three-stage development pathway.

What the Company Does

Ceryvyn Therapeutics' lead asset is CYV-101, a first-in-class fusion protein designed to selectively bind and neutralise VEGF-C and VEGF-D — key signalling proteins involved in pathological lymphangiogenesis. The company's scientific hypothesis is that by targeting this biological pathway, CYV-101 may offer a differentiated therapeutic approach for LAM patients, for whom no cure currently exists.

The company is advancing CYV-101 through a three-stage development program. Stage 1 — currently underway — involves preclinical biology and inhalation studies evaluating the feasibility of nebulising the CYV-101 formulation to align with LAM's lung-centric disease burden. Progression between stages is subject to review against predefined scientific, operational, and Capital allocation criteria reviewed by the Board.

Ceryvyn has established a Scientific Advisory Board (SAB) comprising globally recognised pulmonary and LAM experts. Co-Chairs include Professor Deborah Yates (Sydney, Australia) and Professor Frank McCormack (Ohio, USA), together with Dr Elizabeth Daugherity (Texas, USA). The SAB provides independent scientific and clinical guidance for the LAM program.

Financial and Operational Performance

According to Ceryvyn Therapeutics' Quarterly Activity Report and Appendix 4C for the quarter ended 30 June 2026, published 27 July 2026, the company held AUD $30.0 million in cash and equivalents at 30 June 2026, compared to AUD $31.2 million at 31 March 2026.

Operating cash outflow for the quarter was AUD $1.1 million, compared to AUD $1.5 million in the prior quarter. Research and Development expenses totalled AUD $0.1 million, administration expenses were AUD $1.2 million, and no personnel expenses were incurred during the period. Interest income of AUD $0.2 million was earned. Payments to directors totalled AUD $0.3 million.

Based on the AUD $1.1 million quarterly operating outflow, the company estimated approximately 26.8 quarters of funding available from its cash balance alone — reflecting a capital-efficient operating model at the current stage of development. For the full year to 30 June 2026, net cash used in Operating Activities was AUD $12.5 million, which included prior period expenditure on the former ophthalmology program.

Key Factors Shaping the Business

The strategic pivot from ophthalmology to LAM represents a complete redirection of the company's development focus. Trading in the company's securities was reinstated on the ASX on 3 June 2026 following this decision. The company was subsequently renamed Ceryvyn Therapeutics Limited, with Shareholder approval obtained at an Extraordinary General Meeting on 3 July 2026. The new ASX ticker CYV commenced from 9 July 2026.

The intellectual property position around CYV-101 in LAM has been strengthened during the quarter. The company withdrew two provisional US Patent applications filed in August 2025 and filed a new US provisional patent application focussed on nebulised VEGF inhibitors and their use in pulmonary diseases, including LAM.

Stage 1 preclinical activities include assessment of LAM-relevant biological effects and preliminary safety and tolerability in animal inhalation studies. These studies are described as ongoing and on track. The data generated at Stage 1 will inform the criteria for progression to Stage 2.

Risks and What to Watch

Clinical and scientific risk is the primary consideration for Ceryvyn at this stage. Stage 1 preclinical studies are designed to assess the feasibility of nebulising CYV-101, and the results of these studies will determine whether the program can advance to subsequent stages. Negative or inconclusive data could delay or halt the development program.

While the company's cash position of AUD $30 million provides substantial runway at the current burn rate, expenditure is expected to increase as the program progresses through later development stages. The company's capital management criteria for stage progression will be important in balancing development ambition with financial sustainability.

The LAM patient population is small, which presents both a regulatory pathway opportunity through Orphan Drug designation potential and a commercial challenge in terms of the scale of the addressable market. Competitive development activity in LAM from other organisations, while not detailed in the available disclosures, is a broader risk to monitor.

Key Takeaways

Ceryvyn Therapeutics has completed its rebranding and strategic pivot, and is now focused exclusively on advancing CYV-101 in LAM through a staged preclinical and clinical development program. The company enters this new phase with a substantive cash position of AUD $30 million, a newly established Scientific Advisory Board, and an updated patent strategy. Stage 1 preclinical studies are described as on track. The key near-term milestone is the completion of Stage 1 studies and the Board's assessment of whether the predefined criteria for progression to Stage 2 have been met. The company's capital position provides substantial time to advance these studies before additional funding is required.